ECSP16086217A - Proceso para obtener enantiómeros de pirlindole opticamente activos y sales del mismo - Google Patents

Proceso para obtener enantiómeros de pirlindole opticamente activos y sales del mismo

Info

Publication number
ECSP16086217A
ECSP16086217A ECIEPI201686217A ECPI201686217A ECSP16086217A EC SP16086217 A ECSP16086217 A EC SP16086217A EC IEPI201686217 A ECIEPI201686217 A EC IEPI201686217A EC PI201686217 A ECPI201686217 A EC PI201686217A EC SP16086217 A ECSP16086217 A EC SP16086217A
Authority
EC
Ecuador
Prior art keywords
optically active
salts
enanthyomers
same
obtain optically
Prior art date
Application number
ECIEPI201686217A
Other languages
English (en)
Inventor
Caixado Carlos Alberto Eufrasio Casimiro
Pecorelli Susana Marques Almeida
Ana Sofia Da Conceicao Lopes
Pedroso Pedro Filipe Eufrasio
Joao Carlos Ramos Damil
Oliveira Santos Pedro Paulo De Lacerda E
Filipe Augusto Eugenio Pardal
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of ECSP16086217A publication Critical patent/ECSP16086217A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención proporciona un nuevo procedimiento para obtener enantiómeros de pirlindole ópticamente activos, en forma de una base libre o en forma de sales farmacéuticamente aceptables. Los productos obtenidos según la presente invención son enantioméricamente puros y son útiles en medicina.
ECIEPI201686217A 2014-05-09 2016-11-09 Proceso para obtener enantiómeros de pirlindole opticamente activos y sales del mismo ECSP16086217A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000027 WO2015171003A1 (en) 2014-05-09 2014-05-09 Process for obtaining optically active pirlindole enantiomers and salts thereof

Publications (1)

Publication Number Publication Date
ECSP16086217A true ECSP16086217A (es) 2017-02-24

Family

ID=50819929

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201686217A ECSP16086217A (es) 2014-05-09 2016-11-09 Proceso para obtener enantiómeros de pirlindole opticamente activos y sales del mismo

Country Status (30)

Country Link
US (1) US9682986B2 (es)
EP (1) EP3140265B1 (es)
JP (1) JP6516769B2 (es)
KR (1) KR102258709B1 (es)
CN (1) CN106414376B (es)
AU (1) AU2014393488C1 (es)
BR (1) BR112016025918B1 (es)
CA (1) CA2948604C (es)
CY (1) CY1122367T1 (es)
DK (1) DK3140265T3 (es)
EC (1) ECSP16086217A (es)
ES (1) ES2753403T3 (es)
HR (1) HRP20192029T1 (es)
HU (1) HUE046437T2 (es)
IL (1) IL248853B (es)
LT (1) LT3140265T (es)
MA (1) MA39449A1 (es)
MX (1) MX357918B (es)
NZ (1) NZ726129A (es)
PH (1) PH12016502234A1 (es)
PL (1) PL3140265T3 (es)
PT (1) PT3140265T (es)
RS (1) RS59499B1 (es)
RU (1) RU2666731C2 (es)
SA (1) SA516380265B1 (es)
SI (1) SI3140265T1 (es)
TN (1) TN2016000496A1 (es)
UA (1) UA118696C2 (es)
WO (1) WO2015171003A1 (es)
ZA (1) ZA201607722B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ726127A (en) * 2014-05-09 2019-03-29 Tecnimede Sociedade Tecnico Medicinal S Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
US9682986B2 (en) 2014-05-09 2017-06-20 Tecnimede Sociedade Tecnico-Medicinal S.A. Process for obtaining optically active pirlindole enantiomers and salts thereof
EP3392250A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
EP3392251A1 (en) 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2281085C2 (ru) * 2004-05-25 2006-08-10 Закрытое акционерное общество "Мастерлек" Антидепрессивные лекарственные средства для парентерального применения на основе сульфонатных солей пирлиндола
US9682986B2 (en) 2014-05-09 2017-06-20 Tecnimede Sociedade Tecnico-Medicinal S.A. Process for obtaining optically active pirlindole enantiomers and salts thereof

Also Published As

Publication number Publication date
SI3140265T1 (sl) 2019-12-31
RU2016148181A3 (es) 2018-06-13
EP3140265A1 (en) 2017-03-15
PH12016502234B1 (en) 2017-01-09
MX2016014703A (es) 2017-05-23
BR112016025918A2 (es) 2017-08-15
WO2015171003A1 (en) 2015-11-12
CA2948604C (en) 2021-06-15
CY1122367T1 (el) 2021-01-27
KR20170004995A (ko) 2017-01-11
EP3140265B1 (en) 2019-08-28
RS59499B1 (sr) 2019-12-31
AU2014393488C1 (en) 2020-07-16
LT3140265T (lt) 2019-12-10
HUE046437T2 (hu) 2020-03-30
US20170145024A1 (en) 2017-05-25
ZA201607722B (en) 2022-05-25
CN106414376A (zh) 2017-02-15
CN106414376B (zh) 2019-06-07
RU2016148181A (ru) 2018-06-13
KR102258709B1 (ko) 2021-06-01
MX357918B (es) 2018-07-30
BR112016025918B1 (pt) 2023-05-16
SA516380265B1 (ar) 2019-11-04
RU2666731C2 (ru) 2018-09-12
JP6516769B2 (ja) 2019-05-22
US9682986B2 (en) 2017-06-20
IL248853B (en) 2020-01-30
ES2753403T3 (es) 2020-04-08
HRP20192029T1 (hr) 2020-02-07
UA118696C2 (uk) 2019-02-25
CA2948604A1 (en) 2015-11-12
AU2014393488A1 (en) 2016-11-24
AU2014393488B2 (en) 2018-11-08
PH12016502234A1 (en) 2017-01-09
PT3140265T (pt) 2019-12-02
IL248853A0 (en) 2017-01-31
DK3140265T3 (da) 2019-11-18
MA39449A1 (fr) 2017-11-30
PL3140265T3 (pl) 2020-02-28
TN2016000496A1 (en) 2018-04-04
NZ726129A (en) 2019-03-29
JP2017514883A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
MX2016009862A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
MX2016007636A (es) Metodo para preparar un producto lacteo que tiene un contenido estable de galactooligosacarido(s).
MX2016011547A (es) Metodos y dispositivos para desplegar tendencias y variaciones en un grupo de datos fisiologicos.
CO2017003955A2 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
MX2018007083A (es) Sintesis diaestereoselectiva de derivados de fosfato y del profarmaco de gemcitabina nuc-1031.
AU201612579S (en) Oral care implement
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CY1122367T1 (el) Διαδικασια για την αποκτηση ενεργων οπτικα εναντιομερων πιρλινδολης και των αλατων τους
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
ECSP16086196A (es) Sales farmacéuticamente aceptables de enantiomeros de pirlindole para uso en medicina
CL2017000010A1 (es) Derivados del ácido abscísico sustituido en 3'
CY1124736T1 (el) Διεργασια για την παραγωγη εναντιομερων πυρλινδολης και των αλατων αυτης
BR112017012021A2 (pt) um processo para a fabricação de idalopirdina
GEP20196978B (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
GEAP201914340A (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
TH1601006736A (th) กระบวนการสำหรับการได้รับมาของเพอร์ลินโดลอีแนนทิโอเมอร์ที่แอคทีฟเชิงออพติคอลและเกลือของสิ่งเหล่านี้
PE20170435A1 (es) Sales farmaceuticamente aceptables de enantiomeros de pirlindol para uso en medicina
CL2013002882A1 (es) Metodo para la produccion de formulaciones inyectables de productos proteicos hemoderivados y productos obtenidos utilizando dicho metodo
TH1601006735A (th) เกลือที่ยอมรับได้ทางเภสัชกรรมของเพอร์ลินโดลอีแนนทิโอเมอร์สำหรับ การใช้ในยารักษาโรค
ITUB20153354A1 (it) Macchina e procedimento per la realizzazione di filati, in particolare tecnici.
UA91739U (uk) Спосіб лікування безбольової ішемії міокарда у хворих на артеріальну гіпертензію
ECSDI15000621S (es) Mostrador trilobal